-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that several of the Group's subsidiaries signed a cooperation agreement with Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd. (Enhua), a subsidiary of Jiangsu Enhua Pharmaceutical Co., Ltd., to grant the exclusive commercialization rights of Enhua's three long-acting antipsychotic drug injection products in mainland China. The three products are Recortol (injectable risperidone microspheres (II)), Revalide (paliperidone palmitate injection (II)), and Mibirex (paliperidone palmitate injection), all suitable for the treatment of schizophrenia.

Zhitongcaijing·12/24/2025 09:17:11
Listen to the news
Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that several of the Group's subsidiaries signed a cooperation agreement with Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd. (Enhua), a subsidiary of Jiangsu Enhua Pharmaceutical Co., Ltd., to grant the exclusive commercialization rights of Enhua's three long-acting antipsychotic drug injection products in mainland China. The three products are Recortol (injectable risperidone microspheres (II)), Revalide (paliperidone palmitate injection (II)), and Mibirex (paliperidone palmitate injection), all suitable for the treatment of schizophrenia.